Skip to search formSkip to main contentSkip to account menu

Reolysin

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
A phase II study of intravenous (IV) wild-type reovirus (Reolysin) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung.
10524 Background: Reolysin is a Dearing strain, naturally occurring, ubiquitous human reovirus. The PKR (double stranded RNA… 
2016
2016
Results of a phase II study to evaluate the biological effects of intratumoral (ITu) reolysin in combination with low dose radiotherapy (RT) in patients (Pts) with advanced cancers.
e14514 Background: Reolysin, a wild type reovirus serotype 3 Dearing strain, replicates preferentially in Ras-activated cancer… 
Review
2013
Review
2013
Panorama From the Oncolytic Virotherapy Summit: 7th International Summit on Oncolytic Viral Therapeutics Quebec, Canada, 15-18 June 2013.
In June, the historical heart of Quebec City welcomed the 7th International Summit on Oncolytic Viral Therapeutics for an… 
2013
2013
A multicenter phase I study of intravenous administration of reolysin in combination with irinotecan/fluorouracil/leucovorin (FOLFIRI) in patients (pts) with oxaliplatin-refractory/intolerant KRAS…
450 Background: Reolysin (reovirus serotype 3) contains a naturally occurring, ubiquitous, non-enveloped human dearing strain… 
2013
2013
Abstract C70: A phase 2 study of intravenous administration of REOLYSIN® (reovirus type 3 dearing) in combination with paclitaxel (P) and carboplatin (C) in patients with squamous cell carcinoma of…
Background: REOLYSIN is a unique, dearing strain oncolytic live virus which has demonstrated the ability to replicate in tumor… 
Review
2008
Review
2008
Reovirus therapy in cancer: has the orphan virus found a home?
There has been great interest in the development of oncolytic viruses – viruses that selectively destroy tumour cells – as cancer… 
2008
2008
Phase I/II trial of oncolytic reovirus (Reolysin) in combination with carboplatin/paclitaxel in patients (pts) with advanced solid cancers.
e14519 Background: Reolysin, a wild type reovirus (Dearing strain), replicates preferentially in Ras-activated cancer cells… 
2008
2008
A phase II study of intravenous reolysin (wild-type reovirus) in the treatment of patients with bone and soft tissue sarcomas metastatic to the lung
This Phase II open-label single agent study was designed to characterize the o , us n ng s an v ra e ec s. s a ows rep ca on an… 
2007
2007
A Phase I study to evaluate the feasibility, safety and biological effects of intratumoural administration of wild-type Reovirus (REOLYSIN®) in combination with radiation in patients with advanced…
B81 Background: Wild-type reovirus (REOLYSIN®) is a dsRNA virus which results in asymptomatic infection in humans and has been… 
2006
2006
Reolysin®, an unmodified Reovirus, has significant anti-tumor activity in childhood sarcomas
Proc Amer Assoc Cancer Res, Volume 47, 2006 4331 Reolysin® is an unmodified oncolytic reovirus which replicates selectively in… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)